ZURICH/LONDON, Dec 19 (Reuters) – Roche said on
Friday it would discontinue a late-stage study of an
experimental Alzheimer’s drug after it failed to prove
effective, underlying the difficulty of treating the
The Swiss drugmaker also said a breast cancer trial had
failed to demonstrate the benefit of adding its new drug Kadcyla
to treatment programmes.
LONDON (Reuters) – An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group’s expanding vaccine unit a potential $1 billion boost.
The data suggests the British company’s new shot could be a strong competitor for Merck & Co’s established vaccine Zostavax, which is currently the only product on the market.
BRUSSELS/LONDON (Reuters) – Europe’s top court has opened the door to certain stem cell patents in the European Union by ruling that an organism incapable of developing into a human being is not a human embryo and may be patented.
Thursday’s judgment by the European Court of Justice was made following a case brought in Britain by U.S. company International Stem Cell Corporation over whether it could patent processes covering the use of human egg cells.